Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Jan 16, 2026

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

GlobeNewsWire • Jan 6, 2026

Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).

GlobeNewsWire • Dec 30, 2025

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.

GlobeNewsWire • Dec 24, 2025

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders

GlobeNewsWire • Dec 23, 2025

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.

GlobeNewsWire • Dec 19, 2025

Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet

The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 5, 2025

Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target –

GlobeNewsWire • Dec 4, 2025

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption

GlobeNewsWire • Nov 28, 2025

Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Nov 24, 2025